Biosimilar transition window for tocilizumab, omalizumab, and aflibercept closes May 28, 2026

Under Ontario's biosimilars policy, ODB recipients on originator Eylea (aflibercept), Actemra (tocilizumab), and Xolair (omalizumab) must switch to a biosimilar within the transition period to keep ODB coverage. The window runs Nov 28, 2025 to May 28, 2026 for aflibercept, and to the earlier of May 28, 2026 or the patient's EAP approval expiry for tocilizumab and omalizumab (unless an exception applies). Ensure affected patients are switched and prescriptions reflect the biosimilar.

ScopeUp summarizes Ontario practice updates and links every item to its official source. Verify details against the source document before changing workflows.